 | |
| Clinical data | |
|---|---|
| Other names | Ro 41-3696; Ro41-3696; RO-413696; RO413696 |
| Routes of administration | Oral[1] |
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider |
|
| UNII | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C26H25ClN2O3 |
| Molar mass | 448.95 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
 N Y (what is this?) (verify) | |
Lirequinil (development codeRo 41-3696) is anonbenzodiazepinehypnotic drug which binds tobenzodiazepine sites on theGABAAreceptor.[1] In humanclinical trials, lirequinil was found to have similar efficacy tozolpidem, with less side effects such as clumsiness and memory impairment. However it was also much slower acting than zolpidem, with peak plasma concentrations not reached until 2.5 hours after oral administration, and itsO-desethylmetabolite Ro41-3290 is also active with a half-life of 8 hours.[2][3][4][5] This meant that while effective as a hypnotic, lirequinil failed to prove superior to zolpidem due to producing more next-day sedation, and it has not been adopted for clinical use. It was developed by a team at Hoffmann-La Roche in the 1990s.[6]
